Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.

Bianchini, Elsa P; Fazavana, Judicael; Picard, Veronique; Borgel, Delphine

Bianchini, Elsa P; Fazavana, Judicael; Picard, Veronique; Borgel, Delphine.

Affiliation

Bianchini EP; Université Paris-Sud, Laboratoire d'hématologie, Châtenay-Malabry, France. elsa.bianchini@u-psud.fr

Blood ; 117(6): 2054-60, 2011 Feb 10.

Article in En | MEDLINE | ID: mdl-21048158

Subject(s)

Anticoagulants/antagonists & inhibitors; Antidotes/pharmacology; Antithrombin Proteins/genetics; Antithrombin Proteins/pharmacology; Antithrombins/pharmacology; Heparin Antagonists/pharmacology; Polysaccharides/antagonists & inhibitors; Amino Acid Substitution; Animals; Anticoagulants/toxicity; Drug Design; Female; Fondaparinux; HEK293 Cells; Hemorrhage/chemically induced; Hemorrhage/drug therapy; Humans; Mice; Polysaccharides/toxicity; Recombinant Proteins/genetics; Recombinant Proteins/pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Polysaccharides / Antithrombins / Antithrombin Proteins / Heparin Antagonists / Anticoagulants / Antidotes Type of study: Evaluation_studies Limits: Animals / Female / Humans Language: En Journal: Blood Year: 2011 Type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google